Korean drugmaker Samsung Biologics said on Thursday it plans to split its business into contract manufacturing and development companies, to help allay customer concerns about conflicts of interest.

Samsung Biologics, a biotech arm of South Korea's Samsung Group, said on Thursday it plans to spin off its biosimilar ...

South Korean drug maker Samsung BioLogics said on Thursday it plans to split its business into contract manufacturing and development companies, to help allay customer concerns about conflicts of ...

In 2022, Samsung Biologics acquired Biogen’s remaining shares for $2.3 billion. “This split reflects our decision to enhance competitiveness by responding swiftly to global changes and ...

Shares of Samsung Biologics Co. and its largest holder Samsung C&T Corp. were volatile after the Korean contract drug manufacturer announced a spin-off plan. Investors saw the plan — which will ...

Samsung Biologics, a biotech arm of South Korea's Samsung Group, said Thursday it plans to spin off its biosimilar development b ...

Samsung Biologics Co., the world’s largest contract drugmaker, will undergo a strategic split to separate its contract ...

CDMO weighs plan to build a 6th plant The decision to split the businesses comes in response to industry concerns about conflicts of interest between Samsung Biologics—which contracts with many ...

Samsung may separate its foundry business from its semiconductor division. This move addresses conflict of interest concerns.

Shares in Samsung Biologics rose 7.1 percent the previous day following reports of a possible spinoff and investor optimism about the move. Biologics counts tech giant Samsung Electronics and builder ...

16 for final approval. Samsung Biologics explained that the split will allow the company to concentrate resources on its CDMO business, which operates under a different revenue model compared to ...